Galenica Ag · SIX:GALE
Galenica — FY2025 Earnings Presentation
29 slides from Galenica's earnings presentation, Mar 10, 2026
Slide 1: Media and Analyst Conference
Media and Analyst Conference Galenica | Zurich, 10 March 2026
Slide 2: Annual Results 2025
Annual Results 2025 Julian Fiessinger, CFO Galenica Group
Slide 3: Sales growth supported by acquisition of Labor Team
Galenica Group Sales growth supported by acquisition of Labor Team Net sales (in million CHF) +5.5% 4’136 +4.8% 3’921 3’333 3’180 +6.8% 2024 1’700 1’816 2025 Galenica Group Products & Care Logistics & IT 10 March 2026, Media and Analyst Conference 3
Slide 4: Strong EBIT growth supported by both segments
Strong EBIT growth supported by both segments EBIT adjusted1 (in million CHF) ROS (in %) 5.4% 5.7% 5.5% 234.8 228.6 +8.3% 211.0 61.7 -6.2 55.5 53.8 +3.2% 1.9% 1.7% 1.7% Logistics & IT Products & Care 160.0 175.2 175.2 +9.5% 9.4% 9.6% 9.6% 2 3 2024 2025 one-off 2025 w/o items one-off 1 without effect
Slide 5: Gross margin & Personal cost
Gross margin & Personal cost Overall improvement of gross margin and personal costs Grossmargin % net sales 2024 1 2025 Diff. Galenica Group 27.5% 27.7% 0.2% Products & Care 46.5% 46.2% -0.3% Logistics& IT 9.1% 9.2% 0.1% Personal cost % net sales 2024 1 2025 Diff. Galenica Group 14.9% 14.8% -0.1% Pr
Slide 6: Adjusted Net Profit & Loss Statement
Adjusted Net Profit & Loss Statement1 High prior-year financial result and favourable tax base weighing on net profit growth in million CHF 2024 2025 in % EBITDA 268 294 +9.6% Depreciation property, plant and -37 -35 -5.4% equipment Amortisation intangible assets -20 -24 +21.0% EBIT 211 235 +11.3% R
Slide 7: Investments
Investments Investment in tangible assets below last year 72.8 in million CHF 61.1 36.7 29.4 Investments in intangible assets Investments in tangible assets 36.0 31.8 2024 2025 in % of net sales 1.9% 1.5% 10 March 2026, Media and Analyst Conference 7
Slide 8: Strong balance sheet
Strong balance sheet 1,573 in million CHF 1,509 Equity adjusted1 Net debt adjusted1 675 424 2024 2025 Debt coverage adjusted2 1.6x 2.3x 1 Detail of the adjustments in the Annual Report 2025, see chapter “Alternative performance measures” of the Annual Report 2025 2 Net debt adjusted / EBITDA adjuste
Slide 9: Cash Flow Statement
Cash Flow Statement Significant improvement in operating cash flow in million CHF 2024 2025 Cash flow from operating activities before working 1 224.7 254.5 capital changes adjusted Working capital changes -12.6 -8.8 1 Cash flow from operating activities adjusted 212.1 245.7 Investments in tangible
Slide 10: Dividend Proposal
Dividend Proposal Board of Directors proposes dividend increase of 8.7% 69.9% 68.2% 62.8% 66.5% 64.7% 59.7% 2.50 2.30 2.20 2.20 2.10 1.80 2020 2021 2022 2023 2024 2025 Dividend per share Payout ratio1) 1 Dividend per share in relation to adjusted earnings per share at reporting date 10 March 2026, M
Slide 11: Guidance 2026
Guidance 2026 - Galenica Group net sales +5% to +7% - EBIT adjusted1 +6% to +8% (corresponds +9% to +11% without PY one-off items). The costs associated with the intended closure of Bichsel’s production division will mainly be incurred in the first half of 2026 and are not reflected in the adjusted
Slide 12: Updated mid-term Guidance
Updated mid-term Guidance • Galenica expects net sales to grow by 3% to 5% in the next years. • Segment Logistics & IT: until 2027, Galenica expects a stable development of its return on sales (ROS)1 due to an intense final phase of the ERP project with a planned migration in H2 2026 and subsequent
Slide 13: Strategic Update
Strategic Update Marc Werner, CEO Galenica Group Julian Fiessinger, CFO Galenica Group
Slide 14: The Galenica network
Galenica The Galenica network — ro : © Mediservice + od 2 VERFORA x) iz ' labor team e Qn
Slide 15: Pharmacy as first point of contact
Pharmacy as first point of contact Clear focus Efficiency gains on implementing thanks to digitalisation our growth strategy
Slide 16: 370k pharmacies paid consultations
381 370k pharmacies paid consultations
Slide 17: Prescription manager boosts client retention and satisfaction
Prescription manager boosts client retention and satisfaction
Slide 18: Liberalisation of OTC market not before 2030
Liberalisation of OTC market not before 2030
Slide 19: Shift in product mix towards prescription drugs
Shift in product mix towards prescription drugs lowers dependence on seasonal effects
Slide 20: Continuous efficiency gains
Continuous efficiency gains
Slide 21: 70% automation level at Galexis' Lausanne warehouse
70% automation level at Galexis’ Lausanne warehouse
Slide 22: AI readiness established throughout the network
AI readiness established throughout the network
Slide 23: Investment volume of CHF 80-90 Mio. within the next few years
Investment volume of CHF 80-90 Mio. within the next few years
Slide 24: Growth potential in the physician segment thanks to diagnostics
Growth potential in the physician segment thanks to diagnostics business area
Slide 25: Bichsel and Lifestage Solutions focus on expanding home care
Bichsel and Lifestage Solutions focus on expanding home care business
Slide 26: Products & Brands
Products & Brands Attractive despite flat growth
Slide 27: Our 2026 focus
Our 2026 focus Growth in all business areas Investments in Efficiency gains omni-channel in wholesale
Slide 28: Galenica
Galenica
Slide 29: Disclaimer
Disclaimer Disclaimer Galenica Certain statements, beliefs and opinions in this presentation are forward-looking, which reflect the Company’s or, as appropriate, the Company’s directors’ current expectations and projections about future events. By their nature, forward-looking statements involve a n